Microbiome endpoints in clinical trials for biotics – where do we stand and what have we learnt?
By Marla Cunningham, ISAPP Executive Director I’m sure you’ve read the results of trials similar to these (fictional) conclusions: ‘Our findings showed an increase in Faecalibacterium and Enterococcus, two groups associated with reduced inflammation, and a decrease in Clostridium spp, which have been associated in previous studies with metabolic risk. These results suggest a beneficial […]